Distribution of high-risk human papillomavirus genotypes in HPV-infected women in Beijing, China.

To investigate the distribution of high-risk human papillomavirus (HPV) genotypes in infected women from Beijing, China, samples were obtained during routine gynecologic examinations and DNA was extracted from the samples, and PCR was performed to distinguish the 13 high-risk HPV subtypes (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68). Samples were obtained from 1160 women (20-75 years old), and 470 cases of high-risk HPV infection were diagnosed. HPV 52, HPV 16, HPV 58, HPV 51, and HPV 39 were the most common genotypes accounting for 22.8%, 22.3%, 20.0%, 14.3%, and 13.6% of cases, respectively. The highest infection rates were found in 20-30 year-old patients (35.1%). HPV 16 infection was the highest in the 31-40 year-old group, and HPV 52, HPV 58, and HPV 39 infections were highest in the 20-30 year-old group. Some patients were infected with multiple high-risk HPV subtypes. Of the 470 patients with positive HPV tests, 65.7% of women were infected with a single high-risk HPV subtype, 23.2%, of women were infected with two high-risk HPV subtypes, 7.7% were infected with three subtypes, and 3.4% of women were infected with more than three high-risk HPV subtypes. In this study, HPV 16 and HPV 52 were the most common subtypes found in patients with cervical lesions.

A Linear Relationship Between a Body Shape Index and Risk of Incident Type 2 Diabetes: A Secondary Analysis Based on a Retrospective Cohort Study in Japan.

PURPOSE: This study aimed to evaluate the association between a body shape index (ABSI) and incident type 2 diabetes and to explore the shape of their relationship in a cohort of Japanese adults. PATIENTS AND METHODS: Data from 15,462 Japanese adults aged 18-79 years attending the NAGALA study (NAfld in the Gifu Area, Longitudinal Analysis) were used. Body weight, height, and waist circumference were measured. Blood samples were measured for serum lipid, glucose, and HbA1c. The risk of incident type 2 diabetes according to ABSI was estimated using multivariate Cox regression models. We examined a potential nonlinear relationship using a smoothing function analysis. Subgroup analyses were conducted according to age, gender, smoking status, alcohol intake, fatty liver, and BMI. RESULTS: After adjusting for potential confounding factors (age, gender, smoking status, alcohol intake, fatty liver, systolic blood pressure, BMI, fasting plasma glucose, HbA1c, HDL-cholesterol, triglycerides), a linear relationship was observed between ABSI and risk of type 2 diabetes. The hazard ratio (HR) and 95% confidence intervals (95% CI) for incident type 2 diabetes with ABSI (10-2 m11/6kg-2/3) were 1.51 (1.13, 2.01) (p=0.005). When ABSI was handled as categorical variable, the HRs and 95% CIs in the quartile 2 to 4 versus the quartile 1 were 0.97 (0.67, 1.41), 1.21 (0.85, 1.72) and 1.30 (0.92, 1.83), respectively (P for trend = 0.046). Subgroup analyses showed that the association stably existed in different subgroups including gender, age, smoking status, alcohol intake, fatty liver, and BMI. CONCLUSION: ABSI was linearly associated with an elevated risk of incident type 2 diabetes across the full range of ABSI, independent of gender, age, smoking status, alcohol intake, fatty liver, SBP, BMI, FPG, HbA1c, HDL-cholesterol, and triglycerides.

[Application of High-throughput Sequencing in Acute Myeloid Leukemia Patients with Positive FLT3-ITD].

UNLABELLED: OBJECTICE: To evaluate the application of high-throughput sequencing to sequence the FMS-like Tyrosine Kinase 3 internal tandem duplication (FLT3-ITD) in de novo acute myeloid leukemia (AML) patients with lower allelic ratio FLT3-ITD mutation or more than one ITD, and to analyze the feature of ITD. METHODS: The genomic DNA of 23 AML patients with positive FLT3-ITD was amplified by PCR, capillary electrophoresis was used to detect the ITD mutation. Then, the FLT3 gene was amplified using primer with different barcode, and the product was analyzed by illumina Miseq, and the results were compared with UCSC database. RESULTS: Out of 23 AML patients, 17 had a single ITD, and 3 had 2 ITDs, and the remaining 3 had 3 ITD detected by capillary electrophoresis. The high-throughput sequencing showed that 17 ITD were the complate duplications of wild-type FLT3, and the remaining 16 ITD were partial duplications in the all 33 ITDs. The same length ITD mutation contained 2 different ITD sequences in one patient with more than one ITD, and the other patient with 2 ITD had the same ITD insertion position. The ITD occurred in the regions from p. Y572 to p. L602 of the FLT3 protein, and all the patient ITD covered one or more amino acid between p. V592 and p. E598. CONCLUSION: Illumina Miseq can analyze the sequence of ITDs precisely and accurately. ITD mutation varies widely, but the hotspots are concentrated.

Serum ALDH1A1 is a tumor marker for the diagnosis of non-small cell lung cancer.

BACKGROUND: ALDH1A1 (aldehyde dehydrogenase 1 family, member A1) is highly expressed in non-small-cell lung cancer (NSCLC). We assessed the potential clinical value of serum ALDH1A1 in the diagnosis and prognosis of non-small-cell lung cancer. METHOD: Between 2010 and 2011, serum samples from 100 non-small-cell lung cancer patients before tumor resection, 60 patients with benign lung disease, and 60 healthy volunteers were collected and analyzed retrospectively for ALDH1A1, using sandwich ELISA. We further evaluated the serum and tumor ALDH1A1 levels of non-small-cell lung cancer patients before and after surgery. We compared the diagnostic and prognostic values of serum ALDH1A1 with that of carcinoembryonic antigen. RESULTS: Elevated serum ALDH1A1 levels were observed in 55 of the 100 (55%) non-small-cell lung cancer patients. The ALDH1A1 levels were much higher in patients with advanced stages than in those with early stage tumors. Of the 30 non-small-cell lung cancer patients who underwent surgery, 19 had elevated serum ALDH1A1 levels before surgery, but the serum ALDH1A1 level was undetectable by postoperative day 7. Analysis of receiver operating characteristic curves showed that ALDH1A1 might be better than carcinoembryonic antigen in distinguishing non-small-cell lung cancer from benign disease or the healthy control. Combined application of ALDH1A1 and carcinoembryonic antigen significantly increased the sensitivity of carcinoembryonic antigen alone, with an accuracy of 83%. CONCLUSIONS: Our results showed that serum levels of ALDH1A1 were correlated with carcinogenesis and progression of non-small-cell lung cancer. Detection of serum ALDH1A1 can be helpful in the diagnosis and prognosis of non-small-cell lung cancer. The diagnosis rate of non-small-cell lung cancer could be significantly improved when carcinoembryonic antigen is combined with ALDH1A1.

[Analysis of cytogenetic characteristics in patients with myelodysplastic syndrome].

This study was aimed to investigate the distribution of chromosomal aberrational karyotype in myelodysplastic syndrome (MDS) subgroups, the characterizations of numerical and structural aberration. The chromosome was prepared with simple culture of bone marrow, and the karyotype was analysed by G banding technique. The results showed tht 54 out of 127 patients (42.5%) had clonal chromosome aberrations, and the abnormal rates were different in subgroups: 30% (3/10) in MDS-RA, 35.9% (23/64) in MDS-RCMD, 22.2% (2/9) in MDS-RAS, 45% (9/20) in MDS-RAEB-I, 66.7% (14/21) in MDS-RAEB-II, 100% (3/3) in 5q-syndrome, respectively. Among 54 abnormal chromosome patients, 21 patients showed numerical aberration, 14 patients showed structural aberration, and the other 19 patients showed both numerical and structural aberration. The order of frequent aberrations was as follows complex karyotype (11.02%, 14/127), single +8 (10.24%, 13/127), -7/7q- (3.9%, 5/127), 1q+ (3.15%, 4/127), -X/-Y (3.15%, 4/127), 20q- (2.36%, 3/127), 5q- (2.36%, 3/127). The frequency of complex karyotype in MDS-RAEB (including RAEB-I and RAEB-II) was higher than that in non MDS-RAEB (including RA, RCMD, RAS, 5q-syndrome) (P < 0.05), and the frequency of balanced translocation was lower than that in non-balanced translocation (P < 0.05), and both of the two balanced translocation patients were found in MDS-RAEB. It is concluded that MDS is highly heterogeneous clonal disorder, a great majority of cytogenetic changes can be detected and most of which are recurrent aberrations, balanced translocations are rare, and only found in MDS-RAEB. The frequency of complex karyotype in MDS-RAEB is higher, and the patients with dup (1) (q21q32) recurrent abnormality is common in this study.